Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Who May Qualify: - Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \> 3 months - Participants must have diagnosed by tissue sample (biopsy-confirmed) and documented diagnosis of locally advanced unresectable and/or metastatic sarcoma or a selected solid tumor - Participants must be willing to undergo a tumor biopsy prior to start of treatment or provide archived tumor tissue sample - Participants with sarcoma should have received no more than 2 lines of previous systemic therapies in the metastatic setting - Participants with selected epithelial solid tumors should have received no more than 3 lines of previous systemic therapy in the metastatic/relapsed refractory setting - Participants must have at least one measurable target lesion as defined by RECIST v1.1 - Adequate organ and marrow function as listed per protocol - Must be negative for HIV, HBV, and HCV Who Should NOT Join This Trial: - Participants with another known malignancy that has required treatment within the last 2 years - Symptomatic central nervous system (CNS) metastasis, and/or those requiring therapy with corticosteroids or anticonvulsants to control associated symptoms - Participants with leptomeningeal metastasis - Most recent systemic anti-cancer treatment or investigational products/devices less than 3 weeks - Prior treatment with a topoisomerase-1 inhibitor antibody drug conjugate - Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment - Clinically significant pulmonary disease including autoimmune, connective tissue, or inflammatory conditions - Pregnant or nursing (lactating) women Always talk to your doctor about whether this trial is right for you.